Our job is
STOPPING diseases —
before they start

Initial Therapeutics is pioneering an original mode of disease intervention:

Tackling known, high-value targets via selective termination of protein synthesis in the exit tunnel of the ribosome.

initial therapeutics news

An approach that STOPS disease in its initial stages

We start with targets known to play key roles in disease, and design molecules to enter the ribosome – the machine of the cell itself – to selectively stall the formation of these pathogenic proteins.

ATP IS DEVELOPING THE NEXT GENERATION OF TRANSFORMATIVE LIFE SCIENCES COMPANIES.